{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:11:03Z","timestamp":1781197863594,"version":"3.54.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00296-019-04317-5","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:55:22Z","timestamp":1557449722000},"page":"1135-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Interleukin-17 pathways in systemic sclerosis-associated fibrosis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-311X","authenticated-orcid":false,"given":"Sakir","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1233","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"4317_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557\u2013567. \n                    https:\/\/doi.org\/10.1172\/JCI31139","journal-title":"J Clin Invest"},{"key":"4317_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","volume":"10","author":"R Lafyatis","year":"2014","unstructured":"Lafyatis R (2014) Transforming growth factor \u03b2\u2013at the centre of systemic sclerosis. Nat Rev Rheumatol 10:706\u2013719. \n                    https:\/\/doi.org\/10.1038\/nrrheum.2014.137","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"4317_CR3","doi-asserted-by":"publisher","first-page":"e0030","DOI":"10.5041\/RMMJ.10257","volume":"7","author":"M Baron","year":"2016","unstructured":"Baron M (2016) Targeted therapy in systemic sclerosis. Rambam Maimonides Med J 7(4):e0030. \n                    https:\/\/doi.org\/10.5041\/RMMJ.10257","journal-title":"Rambam Maimonides Med J"},{"key":"4317_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/0973-3698.219083","volume":"12","author":"L Gupta","year":"2017","unstructured":"Gupta L, Ahmed S, Zanwar A (2017) The pathogenesis of scleroderma. Indian J Rheumatol 12:142\u2013148. \n                    https:\/\/doi.org\/10.4103\/0973-3698.219083","journal-title":"Indian J Rheumatol"},{"key":"4317_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","volume":"38","author":"O Distler","year":"2016","unstructured":"Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma\u2013current concepts and novel targets for therapy. Semin Immunopathol 38:87\u201395. \n                    https:\/\/doi.org\/10.1007\/s00281-015-0551-z","journal-title":"Semin Immunopathol"},{"key":"4317_CR6","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630\u20132640. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"4317_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.humimm.2014.12.008","volume":"76","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Hou W, Xu K et al (2015) The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol 76:22\u201329. \n                    https:\/\/doi.org\/10.1016\/j.humimm.2014.12.008","journal-title":"Hum Immunol"},{"key":"4317_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/injr.injr_106_17","volume":"13","author":"A Wakhlu","year":"2018","unstructured":"Wakhlu A, Sahoo RR, Parida JR et al (2018) Serum Interleukin-6, Interleukin-17A, and transforming growth factor beta are raised in systemic sclerosis with interstitial lung disease. Indian J Rheumatol 13:107\u2013112. \n                    https:\/\/doi.org\/10.4103\/injr.injr_106_17","journal-title":"Indian J Rheumatol"},{"key":"4317_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. \n                    https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"4317_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/ard.2009.121053","volume":"70","author":"A Yoshizaki","year":"2011","unstructured":"Yoshizaki A, Yanaba K, Iwata Y et al (2011) Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis 70:194\u2013200. \n                    https:\/\/doi.org\/10.1136\/ard.2009.121053","journal-title":"Ann Rheum Dis"},{"key":"4317_CR11","doi-asserted-by":"publisher","first-page":"e105008","DOI":"10.1371\/journal.pone.0105008","volume":"9","author":"PA Lonati","year":"2014","unstructured":"Lonati PA, Brembilla NC, Montanari E et al (2014) High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS One 9:e105008. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0105008","journal-title":"PLoS One"},{"key":"4317_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00296-018-4071-8","volume":"38","author":"J Tang","year":"2018","unstructured":"Tang J, Lei L, Pan J et al (2018) Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis. Rheumatol Int 38:1511\u20131519. \n                    https:\/\/doi.org\/10.1007\/s00296-018-4071-8","journal-title":"Rheumatol Int"},{"key":"4317_CR13","doi-asserted-by":"publisher","first-page":"e7798","DOI":"10.1371\/journal.pone.0007798","volume":"4","author":"Q Zhang","year":"2009","unstructured":"Zhang Q, Yamaza T, Kelly AP et al (2009) Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17\/IL-6 axis. PLoS One 4:e7798. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0007798","journal-title":"PLoS One"},{"key":"4317_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","volume":"116","author":"GR Hill","year":"2010","unstructured":"Hill GR, Olver SD, Kuns RD et al (2010) Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 116:819\u2013828. \n                    https:\/\/doi.org\/10.1182\/blood-2009-11-256495","journal-title":"Blood"},{"key":"4317_CR15","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","volume":"188","author":"T Nakashima","year":"2012","unstructured":"Nakashima T, Jinnin M, Yamane K et al (2012) Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 188:3573\u20133583. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1100591","journal-title":"J Immunol"},{"key":"4317_CR16","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3389\/fimmu.2018.01865","volume":"9","author":"AM Dufour","year":"2018","unstructured":"Dufour AM, Alvarez M, Russo B, Chizzolini C (2018) Interleukin-6 and Type-I collagen production by systemic sclerosis fibroblasts are differentially regulated by Interleukin-17A in the presence of transforming growth factor-beta 1. Front Immunol 9:1865. \n                    https:\/\/doi.org\/10.3389\/fimmu.2018.01865","journal-title":"Front Immunol"},{"key":"4317_CR17","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.4049\/jimmunol.0901778","volume":"185","author":"A Yoshizaki","year":"2010","unstructured":"Yoshizaki A, Yanaba K, Iwata Y et al (2010) Cell adhesion molecules regulate fibrotic process via Th1\/Th2\/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 185:2502\u20132515. \n                    https:\/\/doi.org\/10.4049\/jimmunol.0901778","journal-title":"J Immunol"},{"key":"4317_CR18","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1002\/art.34643","volume":"64","author":"Y Okamoto","year":"2012","unstructured":"Okamoto Y, Hasegawa M, Matsushita T et al (2012) Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 64:3726\u20133735. \n                    https:\/\/doi.org\/10.1002\/art.34643","journal-title":"Arthritis Rheum"},{"key":"4317_CR19","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3389\/fimmu.2018.01611","volume":"9","author":"M-J Park","year":"2018","unstructured":"Park M-J, Moon S-J, Lee E-J et al (2018) IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis. Front Immunol 9:1611. \n                    https:\/\/doi.org\/10.3389\/fimmu.2018.01611","journal-title":"Front Immunol"},{"key":"4317_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cbin.10410","volume":"39","author":"L Lei","year":"2015","unstructured":"Lei L, Zhong X-N, He Z-Y et al (2015) IL-21 induction of CD4+\u2009T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice. Cell Biol Int 39:388\u2013399. \n                    https:\/\/doi.org\/10.1002\/cbin.10410","journal-title":"Cell Biol Int"},{"key":"4317_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.08.003","volume":"56","author":"A Fran\u00e7ois","year":"2015","unstructured":"Fran\u00e7ois A, Gombault A, Villeret B et al (2015) B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J Autoimmun 56:1\u201311. \n                    https:\/\/doi.org\/10.1016\/j.jaut.2014.08.003","journal-title":"J Autoimmun"},{"key":"4317_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/1756-185X.12522","volume":"19","author":"L Lei","year":"2016","unstructured":"Lei L, He Z-Y, Zhao C et al (2016) Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. Int J Rheum Dis 19:392\u2013404. \n                    https:\/\/doi.org\/10.1111\/1756-185X.12522","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 100","key":"4317_CR23","first-page":"14","volume":"34","author":"L Lei","year":"2016","unstructured":"Lei L, Zhao C, Qin F et al (2016) Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol 34(Suppl 100):14\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"4317_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ajpath.2018.04.005","volume":"188","author":"J Zhang","year":"2018","unstructured":"Zhang J, Qiao Q, Liu M et al (2018) IL-17 promotes scar formation by inducing macrophage infiltration. Am J Pathol 188:1693\u20131702. \n                    https:\/\/doi.org\/10.1016\/j.ajpath.2018.04.005","journal-title":"Am J Pathol"},{"key":"4317_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.yexmp.2009.06.001","volume":"87","author":"W Feng","year":"2009","unstructured":"Feng W, Li W, Liu W et al (2009) IL-17 induces myocardial fibrosis and enhances RANKL\/OPG and MMP\/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 87:212\u2013218. \n                    https:\/\/doi.org\/10.1016\/j.yexmp.2009.06.001","journal-title":"Exp Mol Pathol"},{"key":"4317_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.yexmp.2011.04.003","volume":"91","author":"W Liu","year":"2011","unstructured":"Liu W, Wang X, Feng W et al (2011) Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats. Exp Mol Pathol 91:362\u2013367. \n                    https:\/\/doi.org\/10.1016\/j.yexmp.2011.04.003","journal-title":"Exp Mol Pathol"},{"key":"4317_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cellsig.2011.10.010","volume":"24","author":"AJ Valente","year":"2012","unstructured":"Valente AJ, Yoshida T, Gardner JD et al (2012) Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1\/DUSP-1. Cell Signal 24:560\u2013568. \n                    https:\/\/doi.org\/10.1016\/j.cellsig.2011.10.010","journal-title":"Cell Signal"},{"key":"4317_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/intimm\/dxs056","volume":"24","author":"Y Liu","year":"2012","unstructured":"Liu Y, Zhu H, Su Z et al (2012) IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKC\u03b2\/Erk1\/2\/NF-\u03baB-dependent signaling pathway. Int Immunol 24:605\u2013612. \n                    https:\/\/doi.org\/10.1093\/intimm\/dxs056","journal-title":"Int Immunol"},{"key":"4317_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00109-014-1176-8","volume":"92","author":"S-F Zhou","year":"2014","unstructured":"Zhou S-F, Yuan J, Liao M-Y et al (2014) IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med (Berl) 92:1105\u20131116. \n                    https:\/\/doi.org\/10.1007\/s00109-014-1176-8","journal-title":"J Mol Med (Berl)"},{"key":"4317_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yjmcc.2018.08.005","volume":"122","author":"S-L Chang","year":"2018","unstructured":"Chang S-L, Hsiao Y-W, Tsai Y-N et al (2018) Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure. J Mol Cell Cardiol 122:69\u201379. \n                    https:\/\/doi.org\/10.1016\/j.yjmcc.2018.08.005","journal-title":"J Mol Cell Cardiol"},{"key":"4317_CR31","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.4049\/jimmunol.0902446","volume":"183","author":"SM Faust","year":"2009","unstructured":"Faust SM, Lu G, Marini BL et al (2009) Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol 183:7297\u20137306. \n                    https:\/\/doi.org\/10.4049\/jimmunol.0902446","journal-title":"J Immunol"},{"key":"4317_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ijmm.2015.2204","volume":"36","author":"X-X Fu","year":"2015","unstructured":"Fu X-X, Zhao N, Dong Q et al (2015) Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis. Int J Mol Med 36:83\u201392. \n                    https:\/\/doi.org\/10.3892\/ijmm.2015.2204","journal-title":"Int J Mol Med"},{"key":"4317_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/CIRCHEARTFAILURE.113.000604","volume":"7","author":"K Savvatis","year":"2014","unstructured":"Savvatis K, Pappritz K, Becher PM et al (2014) Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction. Circ Heart Fail 7:161\u2013171. \n                    https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000604","journal-title":"Circ Heart Fail"},{"key":"4317_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/path.4430","volume":"235","author":"X Peng","year":"2015","unstructured":"Peng X, Xiao Z, Zhang J et al (2015) IL-17A produced by both \u03b3\u03b4 T and Th17 cells promotes renal fibrosis via RANTES-mediated leukocyte infiltration after renal obstruction. J Pathol 235:79\u201389. \n                    https:\/\/doi.org\/10.1002\/path.4430","journal-title":"J Pathol"},{"key":"4317_CR35","doi-asserted-by":"publisher","first-page":"F385","DOI":"10.1152\/ajprenal.00462.2016","volume":"312","author":"P Mehrotra","year":"2017","unstructured":"Mehrotra P, Collett JA, McKinney SD et al (2017) IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion: compensatory role of natural killer cells in athymic rats. Am J Physiol Renal Physiol 312:F385\u2013F397. \n                    https:\/\/doi.org\/10.1152\/ajprenal.00462.2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"4317_CR36","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1681\/ASN.2016080840","volume":"28","author":"H-H Chi","year":"2017","unstructured":"Chi H-H, Hua K-F, Lin Y-C et al (2017) IL-36 signaling facilitates activation of the NLRP3 INFLAMMASOME and IL-23\/IL-17 axis in renal inflammation and fibrosis. J Am Soc Nephrol 28:2022\u20132037. \n                    https:\/\/doi.org\/10.1681\/ASN.2016080840","journal-title":"J Am Soc Nephrol"},{"key":"4317_CR37","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3389\/fimmu.2018.02385","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Wang K, Liang X et al (2018) Complement C3 produced by macrophages promotes renal fibrosis via IL-17A secretion. Front Immunol 9:2385. \n                    https:\/\/doi.org\/10.3389\/fimmu.2018.02385","journal-title":"Front Immunol"},{"key":"4317_CR38","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/jphp.12747","volume":"69","author":"A Thorenz","year":"2017","unstructured":"Thorenz A, V\u00f6lker N, Br\u00e4sen JH et al (2017) IL-17A blockade or deficiency does not affect progressive renal fibrosis following renal ischaemia reperfusion injury in mice. J Pharm Pharmacol 69:1125\u20131135. \n                    https:\/\/doi.org\/10.1111\/jphp.12747","journal-title":"J Pharm Pharmacol"},{"key":"4317_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cyto.2017.10.015","volume":"106","author":"B Sun","year":"2018","unstructured":"Sun B, Wang H, Zhang L et al (2018) Role of interleukin 17 in TGF-\u03b2 signaling-mediated renal interstitial fibrosis. Cytokine 106:80\u201388. \n                    https:\/\/doi.org\/10.1016\/j.cyto.2017.10.015","journal-title":"Cytokine"},{"key":"4317_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1681\/ASN.2014111136","volume":"27","author":"R Mohamed","year":"2016","unstructured":"Mohamed R, Jayakumar C, Chen F et al (2016) Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis. J Am Soc Nephrol 27:745\u2013765. \n                    https:\/\/doi.org\/10.1681\/ASN.2014111136","journal-title":"J Am Soc Nephrol"},{"key":"4317_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12882-017-0630-6","volume":"18","author":"W-P Wu","year":"2017","unstructured":"Wu W-P, Tsai Y-G, Lin T-Y et al (2017) The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3+\u2009IL-17+\u2009T cells. BMC Nephrol 18:225. \n                    https:\/\/doi.org\/10.1186\/s12882-017-0630-6","journal-title":"BMC Nephrol"},{"key":"4317_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/wrr.12203","volume":"22","author":"G Wang","year":"2014","unstructured":"Wang G, Wu K, Li W et al (2014) Role of IL-17 and TGF-\u03b2 in peritoneal adhesion formation after surgical trauma. Wound Repair Regen 22:631\u2013639. \n                    https:\/\/doi.org\/10.1111\/wrr.12203","journal-title":"Wound Repair Regen"},{"key":"4317_CR43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1084\/jem.20020028","volume":"195","author":"DR Chung","year":"2002","unstructured":"Chung DR, Chitnis T, Panzo RJ et al (2002) CD4+\u2009T cells regulate surgical and postinfectious adhesion formation. J Exp Med 195:1471\u20131478","journal-title":"J Exp Med"},{"key":"4317_CR44","doi-asserted-by":"publisher","first-page":"e108477","DOI":"10.1371\/journal.pone.0108477","volume":"9","author":"GT Gonz\u00e1lez-Mateo","year":"2014","unstructured":"Gonz\u00e1lez-Mateo GT, Fern\u00e1ndez-M\u00edllara V, Bell\u00f3n T et al (2014) Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. PLoS One 9:e108477. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0108477","journal-title":"PLoS One"},{"key":"4317_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.kint.2015.12.005","volume":"89","author":"E Ferrantelli","year":"2016","unstructured":"Ferrantelli E, Liappas G, Vila Cuenca M et al (2016) The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney Int 89:625\u2013635. \n                    https:\/\/doi.org\/10.1016\/j.kint.2015.12.005","journal-title":"Kidney Int"},{"key":"4317_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1751-2980.2012.00607.x","volume":"13","author":"MY Zhu","year":"2012","unstructured":"Zhu MY, Lu YM, Ou YX et al (2012) Dynamic progress of 2,4,6-trinitrobenzene sulfonic acid induced chronic colitis and fibrosis in rat model. J Dig Dis 13:421\u2013429. \n                    https:\/\/doi.org\/10.1111\/j.1751-2980.2012.00607.x","journal-title":"J Dig Dis"},{"key":"4317_CR47","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ibd.21167","volume":"16","author":"Y Ma","year":"2010","unstructured":"Ma Y, Guan Q, Bai A et al (2010) Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis 16:1040\u20131050. \n                    https:\/\/doi.org\/10.1002\/ibd.21167","journal-title":"Inflamm Bowel Dis"},{"key":"4317_CR48","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.12659\/MSM.904271","volume":"23","author":"L Gu","year":"2017","unstructured":"Gu L, Xu Q, Cao H (2017) 1,25(OH)2D3 protects liver fibrosis through decreasing the generation of TH17 cells. Med Sci Monit 23:2049\u20132058","journal-title":"Med Sci Monit"},{"key":"4317_CR49","doi-asserted-by":"publisher","unstructured":"Wree A, McGeough MD, Inzaugarat ME et al (2017) NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice. Hepatol. \n                    https:\/\/doi.org\/10.1002\/hep.29523\n                    \n                  . (Epub ahead of print)","DOI":"10.1002\/hep.29523"},{"key":"4317_CR50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5604\/16652681.1198820","volume":"15","author":"ASM Zepeda-Morales","year":"2016","unstructured":"Zepeda-Morales ASM, Del Toro-Arreola S, Garc\u00eda-Benavides L et al (2016) Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-\u03b22 expression. Ann Hepatol 15:418\u2013426. \n                    https:\/\/doi.org\/10.5604\/16652681.1198820","journal-title":"Ann Hepatol"},{"key":"4317_CR51","doi-asserted-by":"publisher","first-page":"765-776.e3","DOI":"10.1053\/j.gastro.2012.05.049","volume":"143","author":"F Meng","year":"2012","unstructured":"Meng F, Wang K, Aoyama T et al (2012) Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143:765-776.e3. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2012.05.049","journal-title":"Gastroenterology"},{"key":"4317_CR52","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.4049\/jimmunol.1203013","volume":"191","author":"Z Tan","year":"2013","unstructured":"Tan Z, Qian X, Jiang R et al (2013) IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol 191:1835\u20131844. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1203013\n                    \n                  \n                           (1950)","journal-title":"J Immunol"},{"key":"4317_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar7754","author":"T Fabre","year":"2018","unstructured":"Fabre T, Molina MF, Soucy G et al (2018) Type 3 cytokines IL-17A and IL-22 drive TGF-\u03b2-dependent liver fibrosis. Sci Immunol. \n                    https:\/\/doi.org\/10.1126\/sciimmunol.aar7754","journal-title":"Sci Immunol"},{"key":"4317_CR54","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1067\/mai.2003.1557","volume":"111","author":"J Chakir","year":"2003","unstructured":"Chakir J, Shannon J, Molet S et al (2003) Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 111:1293\u20131298","journal-title":"J Allergy Clin Immunol"},{"key":"4317_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1465-9921-14-34","volume":"14","author":"S Al-Muhsen","year":"2013","unstructured":"Al-Muhsen S, Letuve S, Vazquez-Tello A et al (2013) Th17 cytokines induce pro-fibrotic cytokines release from human eosinophils. Respir Res 14:34. \n                    https:\/\/doi.org\/10.1186\/1465-9921-14-34","journal-title":"Respir Res"},{"key":"4317_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/etm.2018.6145","volume":"16","author":"G Jiang","year":"2018","unstructured":"Jiang G, Liu C-T, Zhang W-D (2018) IL-17A and GDF15 are able to induce epithelial-mesenchymal transition of lung epithelial cells in response to cigarette smoke. Exp Ther Med 16:12\u201320. \n                    https:\/\/doi.org\/10.3892\/etm.2018.6145","journal-title":"Exp Ther Med"},{"key":"4317_CR57","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/path.4359","volume":"233","author":"A Chrysanthopoulou","year":"2014","unstructured":"Chrysanthopoulou A, Mitroulis I, Apostolidou E et al (2014) Neutrophil extracellular traps promote differentiation and function of fibroblasts. J Pathol 233:294\u2013307. \n                    https:\/\/doi.org\/10.1002\/path.4359","journal-title":"J Pathol"},{"key":"4317_CR58","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/mi.2015.85","volume":"9","author":"X Zhou","year":"2016","unstructured":"Zhou X, Loomis-King H, Gurczynski SJ et al (2016) Bone marrow transplantation alters lung antigen-presenting cells to promote TH17 response and the development of pneumonitis and fibrosis following gammaherpesvirus infection. Mucosal Immunol 9:610\u2013620. \n                    https:\/\/doi.org\/10.1038\/mi.2015.85","journal-title":"Mucosal Immunol"},{"key":"4317_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar8356","author":"LJ Celada","year":"2018","unstructured":"Celada LJ, Kropski JA, Herazo-Maya JD et al (2018) PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production. Sci Transl Med. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aar8356","journal-title":"Sci Transl Med"},{"key":"4317_CR60","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty D, \u0160umov\u00e1 B, Mallano T et al (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8:1130. \n                    https:\/\/doi.org\/10.1038\/s41467-017-01236-6","journal-title":"Nat Commun"},{"key":"4317_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18:153\u2013167. \n                    https:\/\/doi.org\/10.1038\/nri.2017.108","journal-title":"Nat Rev Immunol"},{"key":"4317_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11912-018-0671-4","volume":"20","author":"LA Kottschade","year":"2018","unstructured":"Kottschade LA (2018) Incidence and management of immune-related adverse events in patients undergoing treatment with immune checkpoint inhibitors. Curr Oncol Rep 20:24. \n                    https:\/\/doi.org\/10.1007\/s11912-018-0671-4","journal-title":"Curr Oncol Rep"},{"key":"4317_CR63","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1038\/s41467-018-05768-3","volume":"9","author":"A Zehender","year":"2018","unstructured":"Zehender A, Huang J, Gy\u00f6rfi A-H et al (2018) The tyrosine phosphatase SHP2 controls TGF\u03b2-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nat Commun 9:3259. \n                    https:\/\/doi.org\/10.1038\/s41467-018-05768-3","journal-title":"Nat Commun"},{"key":"4317_CR64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1083\/jcb.201204106","volume":"200","author":"Z Ahmed","year":"2013","unstructured":"Ahmed Z, Lin C-C, Suen KM et al (2013) Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity. J Cell Biol 200:493\u2013504. \n                    https:\/\/doi.org\/10.1083\/jcb.201204106","journal-title":"J Cell Biol"},{"key":"4317_CR65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4049\/jimmunol.171.1.257","volume":"171","author":"JG Bode","year":"2003","unstructured":"Bode JG, Schweigart J, Kehrmann J et al (2003) TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex. J Immunol 171:257\u2013266","journal-title":"J Immunol"},{"key":"4317_CR66","doi-asserted-by":"publisher","first-page":"22353","DOI":"10.1074\/jbc.M109.020495","volume":"284","author":"W Zhang","year":"2009","unstructured":"Zhang W, Chan RJ, Chen H et al (2009) Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. J Biol Chem 284:22353\u201322363. \n                    https:\/\/doi.org\/10.1074\/jbc.M109.020495","journal-title":"J Biol Chem"},{"key":"4317_CR67","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/cdd.2008.54","volume":"15","author":"X-D Zhou","year":"2008","unstructured":"Zhou X-D, Agazie YM (2008) Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ 15:988\u2013996. \n                    https:\/\/doi.org\/10.1038\/cdd.2008.54","journal-title":"Cell Death Differ"},{"key":"4317_CR68","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","volume":"20","author":"CR Maroun","year":"2000","unstructured":"Maroun CR, Naujokas MA, Holgado-Madruga M et al (2000) The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 20:8513\u20138525","journal-title":"Mol Cell Biol"},{"key":"4317_CR69","doi-asserted-by":"publisher","first-page":"e49943","DOI":"10.1371\/journal.pone.0049943","volume":"7","author":"YH Tsang","year":"2012","unstructured":"Tsang YH, Han X, Man WY et al (2012) Novel functions of the phosphatase SHP2 in the DNA replication and damage checkpoints. PLoS One 7:e49943. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0049943","journal-title":"PLoS One"},{"key":"4317_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21767\/2573-5365.100037","volume":"3","author":"AJ Fisher","year":"2017","unstructured":"Fisher AJ, Cipolla E, Varre A et al (2017) Potential mechanisms underlying TGF-\u03b2-mediated complement activation in lung fibrosis. Cell Mol Med Open Access 3:14","journal-title":"Cell Mol Med Open Access"},{"key":"4317_CR71","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1096\/fj.201700289R","volume":"31","author":"E Cipolla","year":"2017","unstructured":"Cipolla E, Fisher AJ, Gu H et al (2017) IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis. FASEB J 31:5543\u20135556. \n                    https:\/\/doi.org\/10.1096\/fj.201700289R","journal-title":"FASEB J"},{"key":"4317_CR72","first-page":"2148","volume":"10","author":"X Chen","year":"2018","unstructured":"Chen X, Lai P, Wang Y et al (2018) Emerging role of C5a\/C5aR IL-17A axis in cGVHD. Am J Transl Res 10:2148\u20132157","journal-title":"Am J Transl Res"},{"key":"4317_CR73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.metabol.2015.01.014","volume":"64","author":"L Li","year":"2015","unstructured":"Li L, Chen L, Zang J et al (2015) C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt\/\u03b2-catenin signaling pathway in diabetic kidney disease. Metabolism 64:597\u2013610. \n                    https:\/\/doi.org\/10.1016\/j.metabol.2015.01.014","journal-title":"Metabolism"},{"key":"4317_CR74","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/ndt\/gfx336","volume":"33","author":"WH Yiu","year":"2017","unstructured":"Yiu WH, Li RX, Wong DWL et al (2017) Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrol Dial Transplant 33:1323\u20131332. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfx336","journal-title":"Nephrol Dial Transplant"},{"key":"4317_CR75","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1096\/fj.201500044","volume":"30","author":"H Gu","year":"2016","unstructured":"Gu H, Fisher AJ, Mickler EA et al (2016) Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis. FASEB J 30:2336\u20132350. \n                    https:\/\/doi.org\/10.1096\/fj.201500044","journal-title":"FASEB J"},{"key":"4317_CR76","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L et al (2017) Randomized Trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28:2756\u20132767. \n                    https:\/\/doi.org\/10.1681\/ASN.2016111179","journal-title":"J Am Soc Nephrol"},{"key":"4317_CR77","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1073\/pnas.0710468105","volume":"105","author":"K Hellmuth","year":"2008","unstructured":"Hellmuth K, Grosskopf S, Lum CT et al (2008) Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci USA 105:7275\u20137280","journal-title":"Proc Natl Acad Sci USA"},{"key":"4317_CR78","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE et al (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 123:3390\u20133397","journal-title":"Blood"},{"key":"4317_CR79","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","volume":"10","author":"LH Calabrese","year":"2014","unstructured":"Calabrese LH, Rose-John S (2014) IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10:720\u2013727","journal-title":"Nat Rev Rheumatol"},{"key":"4317_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","volume":"1","author":"LM Ballou","year":"2008","unstructured":"Ballou LM, Lin RZ (2008) Rapamycin and mTOR kinase inhibitors. J Chem Biol 1:27\u201336","journal-title":"J Chem Biol"},{"key":"4317_CR81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jdermsci.2017.06.010","volume":"87","author":"FC Kurschus","year":"2017","unstructured":"Kurschus FC, Moos S (2017) IL-17 for therapy. J Dermatol Sci 87:221\u2013227","journal-title":"J Dermatol Sci"},{"key":"4317_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/wdev.86","volume":"2","author":"A Weiss","year":"2013","unstructured":"Weiss A, Attisano L (2013) The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol 2:47\u201363. \n                    https:\/\/doi.org\/10.1002\/wdev.86","journal-title":"Wiley Interdiscip Rev Dev Biol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04317-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T23:09:52Z","timestamp":1588892992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04317-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["4317"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04317-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]},"assertion":[{"value":"11 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sakir Ahmed declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Vikas Agarwal declares that he has no conflict of interest, including no relationship with pharmaceutical companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}